Cargando…
Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406343/ https://www.ncbi.nlm.nih.gov/pubmed/22844580 http://dx.doi.org/10.1038/srep00539 |
_version_ | 1782239223867244544 |
---|---|
author | Antoon, James W. Lai, Rongye Struckhoff, Amanda P. Nitschke, Ashley M. Elliott, Steven Martin, Elizabeth C. Rhodes, Lyndsay V. Yoon, Nam Seung Salvo, Virgilio A. Shan, Bin Beckman, Barbara S. Nephew, Kenneth P. Burow, Matthew E. |
author_facet | Antoon, James W. Lai, Rongye Struckhoff, Amanda P. Nitschke, Ashley M. Elliott, Steven Martin, Elizabeth C. Rhodes, Lyndsay V. Yoon, Nam Seung Salvo, Virgilio A. Shan, Bin Beckman, Barbara S. Nephew, Kenneth P. Burow, Matthew E. |
author_sort | Antoon, James W. |
collection | PubMed |
description | Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer cell line to tumor necrosis factor (TNF) was associated with loss of ER expression and a multi-drug resistant phenotype. Changes in three major pathways were involved in this transition to a multidrug resistance phenotype: ER, Death Receptor and epithelial to mesenchymal transition (EMT). Resistant cells exhibited altered ER signaling, resulting in decreased ER target gene expression. The death receptor pathway was significantly altered, blocking extrinsic apoptosis and increasing NF-kappaB survival signaling. TNF resistance promoted EMT changes, resulting in a more aggressive phenotype. This first report identifying specific mechanisms underlying acquired resistance to TNF could lead to a better understanding of the progression of breast cancer in response to chemotherapy treatment. |
format | Online Article Text |
id | pubmed-3406343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34063432012-07-27 Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance Antoon, James W. Lai, Rongye Struckhoff, Amanda P. Nitschke, Ashley M. Elliott, Steven Martin, Elizabeth C. Rhodes, Lyndsay V. Yoon, Nam Seung Salvo, Virgilio A. Shan, Bin Beckman, Barbara S. Nephew, Kenneth P. Burow, Matthew E. Sci Rep Article Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer cell line to tumor necrosis factor (TNF) was associated with loss of ER expression and a multi-drug resistant phenotype. Changes in three major pathways were involved in this transition to a multidrug resistance phenotype: ER, Death Receptor and epithelial to mesenchymal transition (EMT). Resistant cells exhibited altered ER signaling, resulting in decreased ER target gene expression. The death receptor pathway was significantly altered, blocking extrinsic apoptosis and increasing NF-kappaB survival signaling. TNF resistance promoted EMT changes, resulting in a more aggressive phenotype. This first report identifying specific mechanisms underlying acquired resistance to TNF could lead to a better understanding of the progression of breast cancer in response to chemotherapy treatment. Nature Publishing Group 2012-07-27 /pmc/articles/PMC3406343/ /pubmed/22844580 http://dx.doi.org/10.1038/srep00539 Text en Copyright © 2012, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareALike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Article Antoon, James W. Lai, Rongye Struckhoff, Amanda P. Nitschke, Ashley M. Elliott, Steven Martin, Elizabeth C. Rhodes, Lyndsay V. Yoon, Nam Seung Salvo, Virgilio A. Shan, Bin Beckman, Barbara S. Nephew, Kenneth P. Burow, Matthew E. Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance |
title | Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance |
title_full | Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance |
title_fullStr | Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance |
title_full_unstemmed | Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance |
title_short | Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance |
title_sort | altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406343/ https://www.ncbi.nlm.nih.gov/pubmed/22844580 http://dx.doi.org/10.1038/srep00539 |
work_keys_str_mv | AT antoonjamesw altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT lairongye altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT struckhoffamandap altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT nitschkeashleym altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT elliottsteven altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT martinelizabethc altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT rhodeslyndsayv altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT yoonnamseung altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT salvovirgilioa altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT shanbin altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT beckmanbarbaras altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT nephewkennethp altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance AT burowmatthewe altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance |